Sonnet biotherapeutics announces fda clearance of its ind for son-1010 for the treatment of advanced solid tumors

Represents sonnet's first ind cleared phase 1 trial initiation expected in 2q22 princeton, nj / accesswire / march 16, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced that the u.s. food and drug administration (fda) has cleared the company's investigational new drug (ind) application for son-1010, a proprietary version of interleukin 12 (il-12) configured using sonnet's fully human albumin binding (fhab™) technology. this will allow sonnet to initiate its first-in-human phase 1 trial in adult oncology patients in the second quarter of 2022.
SONN Ratings Summary
SONN Quant Ranking